Status:
COMPLETED
IMPACT-CABG Trial: IMPlantation of Autologous CD133+ sTem Cells in Patients Undergoing Coronary Artery Bypass Grafting
Lead Sponsor:
University Health Network, Toronto
Collaborating Sponsors:
Miltenyi Biotec, Inc.
Conditions:
Heart Failure
Heart Attack
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
Following myocardial infarct, cellular therapy is a potential approach to repopulate the injured myocardium, to treat heart failure and restore cardiac function. The purpose of this study is to assess...
Detailed Description
CD133+ are well characterized distinct early progenitor group of stem cells that possess high engraftment, pluripotent and angiogenic capacity and proved to be valuable for cardiac repair by promoting...
Eligibility Criteria
Inclusion
- Age ≥18 years, and ≤75 years.
- Patients with severe chronic ischemic cardiomyopathy manifested by Canadian Cardiovascular Society (CCS) class II or greater angina, and/or New York Heart Association (NYHA) class II or greater dyspnea, AND who have undergone diagnostic coronary angiography demonstrating ≥70% diameter narrowing of at least two major coronary arteries or branches or ≥50% diameter narrowing of the left main coronary artery.
- Significant left ventricular systolic dysfunction evaluated by echocardiography or LV angiography (LV ejection fraction ≤45% but ≥25%) due to a prior myocardial infarction. This area of left ventricular dysfunction should be akinetic or severely hypokinetic, not dyskinetic or aneurysmal, when assessed by echocardiography or LV angiogram.
- No contraindications or exclusions (see below).
- Willingness to participate and ability to provide informed consent.
Exclusion
- contraindications to magnetic resonance imaging (MRI) including presence of an implantable cardiac defibrillator (ICD) or permanent pacemaker (PPM), or cases in which it is anticipated that an ICD or PPM will be implanted prior to the 6 month follow-up or claustrophobia (thus precluding performance of follow-up MRI scans).
- Need for urgent or emergent revascularization.
- Anticipated for concomitant surgical procedure at the time of CABG (e.g. valve repair or replacement, aneurysm resection, etc.).
- Hemodynamically unstable patients, as defined by heart rate ≤40/min or ≥100/min, and/or systolic blood pressure \<90 mmHg or ≥200 mmHg, and/or ongoing need for intravenous inotropic or vasopressor medications.
- Patients with confirmed myocardial infarction within 14 days, and/or rising cardiac biomarker proteins (i.e. CK-MB or troponin), and/or worsening ECG changes.
- Prior CABG surgery.
- Stroke within 3 months prior to plan CABG.
- Immunosuppressive medication (e.g. prednisone, cyclophosphamide, etanercept, etc.)
- Severe chronic renal insufficiency (serum creatinine ≥ 200 mmol/dl or need for dialysis),liver disease, (diagnosis of cirrhosis, chronic hepatitis, or elevated serum transaminases ≥3 times the upper limit of normal), cerebrovascular disease requiring concomitant carotid endarterectomy, peripheral arterial disease (claudication as the primary factor limiting activity), active non-dermatological malignancy requiring on-going treatment, or any other condition that would place the patient at increased risk for complications during the first 6 months after the procedure in the judgement of the attending cardiologist or cardiac surgeon.
- Contra-indication to bone marrow aspiration (Thrombocytopenia \<50,000 mm3, INR \>2.0 ).
- Hemoglobin less than 10g/dL, white blood cell count less than 4,000/mm3, absolute neutrophil count less than 1500/mm3
- Active infection, with a temperature greater than 37.5°C within 48 hours prior to surgery and an unexplained white blood cell count in excess of 10,000/mm3
- Myelodysplastic syndrome
- Significant cognitive impairment
- Any condition associated with a life expectancy of less than 6 months
- Known allergic reaction or contraindication to any of the components of the CD133+ enriched cells
- Participation in other studies
- History of severe ventricular tachyarrhythmia's requiring treatment
- Positive laboratory test results or a history of syphilis, Hepatitis B Virus, Hepatitis C Virus, Human T-Lymphotropic Virus Type 1 and 2, and Human Immunodeficiency Virus.
- Pregnant woman
- Inability or unwillingness to provide written informed consent
Key Trial Info
Start Date :
September 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2015
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT01467232
Start Date
September 1 2011
End Date
October 1 2015
Last Update
December 2 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peter Munk Cardiac Center/ University Health Network
Toronto, Ontario, Canada, M5G 2C4